The International Myositis Assessment and Clinical Studies Group (IMACS) recently published the first evidence- and consensus-based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.1 Given the well-documented association between dermatomyositis and cancer,2-5 these recommendations standardize cancer screening guidance by stratifying patients with high, intermediate, or low risk for cancer based on factors including myositis subtype, age at disease onset, autoantibody profiles, and clinical features.1 Recommendations include serologic tests and/or imaging tailored to patient risk. Low-risk patients should have basic cancer screening (routine blood and urine studies, plain chest radiography, and age- and sex-appropriate cancer screening), and intermediate- or high-risk patients should have enhanced cancer screening (computed tomography of the neck, thorax, abdomen, and pelvis, pelvic and transvaginal ultrasonography, Papanicolaou testing, mammography, prostate-specific antigen or cancer antigen 125 blood tests, and fecal occult blood test).1 However, the performance of these cancer screening recommendations has not been empirically investigated.